Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 May;88(2):253-7.
doi: 10.1111/j.1365-2249.1992.tb03069.x.

Specificity of IgG subclass antibodies in different clinical manifestations of leprosy

Affiliations

Specificity of IgG subclass antibodies in different clinical manifestations of leprosy

S Dhandayuthapani et al. Clin Exp Immunol. 1992 May.

Abstract

We analysed specific IgG subclasses levels to Mycobacterium leprae sonicate extract (MSE), lipoarabinomannan B (LAM) and phenolic glycolipid I (PGL-I) in the sera of leprosy patients with different clinical manifestations. IgG2 was found to be the predominant antibody to MSE regardless of clinical manifestations, and IgG1 response was mostly seen in lepromatous patients. IgG3 reacted only rarely but IgG4 reacted relatively more in certain clinical groups such as borderline lepromatous and lepromatous with erythema nodosum leprosum (ENL) reaction. Most of the IgG subclass responses to MSE could be accounted for reactivity with LAM, suggesting that LAM is the major immunogen involved in the pathogenesis of leprosy. In contrast to LAM, PGL-I antigen showed considerably lower reactivities for IgG subclasses. An association between IgG subclass responses and clinical manifestations of leprosy was also seen. Whereas borderline lepromatous patients were found to have significantly higher levels of IgG2 and IgG4 to MSE, lepromatous patients had elevated levels of IgG1 and lower levels of IgG2. An interesting observation, however, was the significantly higher levels of IgG2 to LAM in the pure neuritic leprosy patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 1987 May 1;138(9):3028-34 - PubMed
    1. Indian J Lepr. 1987 Apr-Jun;59(2):178-87 - PubMed
    1. J Clin Microbiol. 1988 Dec;26(12):2474-9 - PubMed
    1. Monogr Allergy. 1986;19:134-43 - PubMed
    1. Monogr Allergy. 1986;19:122-33 - PubMed

MeSH terms